Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

1. Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults

Tenapanor (Ibsrela) - irritable bowel syndrome with constipation in adults Drug Approval Package: IBSRELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: IBSRELA Company: Ardelyx, Inc. Application Number: 211801 Approval Date: 09/12/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2019 FDA - Drug Approval Package

3. A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation

A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation To determine patient preference for treating opioid-induced constipation (OIC) using naloxegol or polyethylene glycol (PEG) 3350 in patients receiving opioids for noncancer pain.This crossover study included two 2-week active treatment periods, each preceded by a 1-week washout period (NCT03060512). Individuals with baseline

2019 EvidenceUpdates

4. Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines

Naldemedine (Rizmoic) - treating constipation caused by opioid pain relief medicines 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/21684/2019 EMEA/H/C/004256 Rizmoic An overview of Rizmoic and why it is authorised in the EU (...) What is Rizmoic and what is it used for? Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements). It contains the active substance naldemedine. How is Rizmoic used? Rizmoic is available as 200 microgram tablets. The recommended dose is one tablet once daily, which the patient can take with or without a laxative. The patient must stop taking Rizmoic when

2019 European Medicines Agency - EPARs

5. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation

American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Access provided by Volume 156, Issue 1, Pages 218–226 American Gastroenterological Association Institute Guideline on the Medical Management of Opioid (...) -Induced Constipation x Seth D. Crockett Affiliations Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina Correspondence Reprint requests Address requests for reprints to: Seth D. Crockett, MD, MPH, Division of Gastroenterology and Hepatology, University of North Carolina, CB 7080, 130 Mason Farm Road, Chapel Hill, North Carolina 27599. fax: (919) 966-8929. 1 , ∗ , x Seth D. Crockett Affiliations Division of Gastroenterology

2019 American Gastroenterological Association Institute

6. Constipation in children

Constipation in children Constipation in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Constipation in children Last reviewed: February 2019 Last updated: February 2019 Summary Childhood constipation is typically characterised by infrequent bowel evacuations, large stools, and difficult or painful defecation. Symptoms may result from low fibre, poor nutrient, and/or insufficient water intake, which leads (...) to excessive hardening of the stool. This often starts as an acute problem but can progress to faecal impaction and chronic constipation. Particularly in young children, any cause of painful defecation may provoke active withholding. Withholding may worsen the constipation and lead to a vicious cycle. Duration of constipation and amount of stool burden may depend on capacity of the child's rectum, the degree of megarectum, and other factors including rectal sensory function. After faecal disimpaction

2019 BMJ Best Practice

7. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain Oral methylnaltrexone was shown to be effective in treating opioid-induced constipation (OIC) in patients with chronic noncancer pain in a Phase III randomized controlled trial. This report provides a detailed safety analysis from that study.Adults (n=803) with chronic noncancer pain for ≥2 months and confirmed OIC while receiving opioid doses ≥50 mg morphine equivalent per day for ≥14 days

2019 EvidenceUpdates

8. Acupressure effect on constipation: systematic review and meta-analysis

Acupressure effect on constipation: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2019 PROSPERO

9. A systematic review and meta-analysis of the efficacy of probiotics in the treatment of functional constipation in children

A systematic review and meta-analysis of the efficacy of probiotics in the treatment of functional constipation in children Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

10. To explore the effects of medical and lifestyle interventions on constipation for patients with chronic kidney disease

To explore the effects of medical and lifestyle interventions on constipation for patients with chronic kidney disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

11. Systematic review of interventions for the prevention and treatment of constipation in adult patients with cancer, including opioid-induced constipation and general constipation

Systematic review of interventions for the prevention and treatment of constipation in adult patients with cancer, including opioid-induced constipation and general constipation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

12. Efficacy of peripherally acting mu-opioid antagonist for the treatment of opioid-induced constipation: multiple treatment comparisons in a network meta-analysis

Efficacy of peripherally acting mu-opioid antagonist for the treatment of opioid-induced constipation: multiple treatment comparisons in a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

13. Massage for preventing postpartum constipation: a systematic review and meta-analysis

Massage for preventing postpartum constipation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

14. Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis

Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

15. Effectiveness and safety of lactobacillus in children with functional constipation: a meta-analysis and systematic review

Effectiveness and safety of lactobacillus in children with functional constipation: a meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

16. Tuina for functional constipation: a systematic review of randomized controlled trials

Tuina for functional constipation: a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

17. Placebo response rate in patients with chronic constipation

Placebo response rate in patients with chronic constipation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

18. Auricular point taping for constipation in patients with stroke: a cumulative meta-analysis

Auricular point taping for constipation in patients with stroke: a cumulative meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

19. Acupuncture at Tianshu (ST25) for functional constipation: a systematic review and meta-analysis

Acupuncture at Tianshu (ST25) for functional constipation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

20. Constipation

Constipation Constipation - NICE CKS Share Constipation: Summary Constipation is a symptom-based disorder which describes defecation that is unsatisfactory because of infrequent stools, difficulty passing stools, or the sensation of incomplete emptying. The Rome IV diagnostic criteria for constipation include spontaneous bowel movements occurring less than three times a week. Chronic constipation usually describes symptoms which are present for at least 12 weeks in the preceding six months (...) . Faecal loading/impaction describes retention of faeces to the extent that spontaneous evacuation is unlikely. Functional (primary or idiopathic)constipation is chronic constipation without a known cause. Secondary (organic) constipation is constipation caused by a drug or underlying medical condition. Constipation may occur at any age but is more common in women, the elderly, and during pregnancy. Assessment of a person with constipation should include: Any red flag symptoms or signs that may suggest

2019 NICE Clinical Knowledge Summaries